Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Casirivimab/Imdevimab: Possible Candidate for COVID-19 Treatment in Pets: Traditional Review
Casirivimab/İmdevimab: Evcil Hayvanlarda COVID-19 Tedavisi İçin Olası Bir Aday: Geleneksel Derleme
Fatma ENDERa, Serkan SAYINERb,c, Sevgi GENÇOSMANb,c, Deniz CEYLANLIb,c, Güzin ÖZKURTd , Nurettin ABACIOĞLUe , Ahmet Özer ŞEHİRLİf
aDepartment of Surgery, Near East University Faculty of Veterinary Medicine, Nicosia, Turkish Republic of Northern Cyprus
bDepartment of Biochemistry, Near East University Faculty of Veterinary Medicine, Nicosia, Turkish Republic of Northern Cyprus
cDiagnostic Laboratory, Near East University Animal Hospital, Nicosia, Turkish Republic of Northern Cyprus
dDepartment of Biochemistry, Aksaray University Faculty of Veterinary Medicine, Aksaray, Türkiye
eDepartment of Pharmacology, Near East University Faculty of Pharmacy, Nicosia, Turkish Republic of Northern Cyprus
fDepartment of Pharmacology, Near East University Faculty of Dentistry, Nicosia, Turkish Republic of Northern Cyprus
Turkiye Klinikleri J Vet Sci. 2023;14(1):22-7
doi: 10.5336/vetsci.2022-92555
Article Language: EN
Full Text
ABSTRACT
 The coronavirus disease-2019 (COVID-19), over the last 3 years has globally resulted in catastrophic widespread losses. Prevention and control of this disease has become a global priority for researchers and medical professionals due to high mortality rates, treatment costs and various losses (economic and fatalities). In recent times, the fact that cats and dogs living in households which are being affected by the disease has caused panic among pet owners and animal lovers. Studies have shown that cats, especially young cats, are the group of animals which are most affected. Therefore, the treatment of COVID-19 in animals is an important topic for veterinary medicine. Monoclonal antibodies have also been considered a possible treatment modality due to the use of various agents to treat COVID-19 and the lack of clear demonstration of their efficacy. Casirivimab/imdevimab (CAS/IMD) is a monoclonal antibody cocktail approved for treating COVID-19. There was a high expectation that CAS/IMD combination directly affects the angiotensin converting enzyme-2 receptors, which plays an important role in the pathogenesis of the virus. Experimental and clinical studies have shown that CAS/IMD combination positively affects the prognosis of patients suffering from COVID-19, speeds up the recovery process and increases survival. We suggest that CAS/IMD can be considered protective in COVID-19 positive dogs and cats. The aim of this article is to review the studies related to the beneficial effects of CAS/IMD and its possible effectiveness in animals with COVID-19 to promote their research in future studies.

Keywords: Casirivimab; imdevimab; COVID-19; pet animals; monoclonal antibody
ÖZET
 Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID19)], son 3 yılda küresel olarak trajik yaygın kayıplara neden oldu. Bu hastalığın önlenmesi ve kontrolü; yüksek ölüm oranları, tedavi maliyetleri ve diğer çeşitli kayıplar (ekonomik ve ölümler) nedeniyle araştırmacılar ve medikal uzmanları için küresel bir öncelik hâline gelmiştir. Son zamanlarda hastalıktan etkilenen hanelerde yaşayan kedi ve köpeklerin olması, evcil hayvan sahipleri ve hayvanseverler arasında da paniğe neden oldu. Araştırmalar, kedilerin, özellikle genç kedilerin, en çok etkilenen hayvan grubu olduğunu göstermiştir. Bu nedenle hayvanlarda COVID-19 tedavisi veteriner hekimliği için önemli bir konudur. Monoklonal antikorlar, COVID-19'u tedavi etmek için çeşitli ajanların kullanılması ve etkinliklerinin net bir şekilde gösterilmemesi nedeniyle olası bir tedavi yöntemi olarak kabul edilmiştir. Casirivimab/imdevimab (CAS/IMD), COVID-19 tedavisi için onaylanmış bir monoklonal antikor kokteylidir. CAS/IMD kombinasyonunun, virüsün patogenezinde önemli bir rol oynayan anjiyotensin dönüştürücü enzim-2 reseptörlerini doğrudan etkilediği yönünde yüksek bir beklenti vardı. Deneysel ve klinik çalışmalar, CAS/IMD kombinasyonunun, COVID-19'dan muzdarip hastaların prognozunu olumlu yönde etkilediğini, iyileşme sürecini hızlandırdığını ve sağkalım oranını artırdığını göstermiştir. Dolayısıyla CAS/IMD'nin COVID-19 pozitif köpek ve kedilerde koruyucu olarak kabul edilebileceğini öneriyoruz. Bu derlemenin amacı, CAS/IMD'nin faydalı etkileri ile ilgili çalışmaları ve gelecekteki araştırmaları teşvik etmek için COVID-19'lu hayvanlarda CAS/IMD'nin olası etkinliğinin gözden geçirilmesidir.

Anahtar Kelimeler: Casirivimab; imdevimab; COVID-19; pet hayvanlar; monoklonal antikor
REFERENCES:
  1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92(4):401-2. [Crossref]  [PubMed]  [PMC] 
  2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. [Crossref]  [PubMed]  [PMC] 
  3. Nicholas T, Mandaah FV, Esemu SN, Vanessa ABT, Gilchrist KTD, Vanessa LF, et al. COVID-19 knowledge, attitudes and practices in a conflict affected area of the South West Region of Cameroon. Pan Afr Med J. 2020;35(Suppl 2):34. [Crossref]  [PubMed]  [PMC] 
  4. Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 2020;129:110337. [Crossref]  [PubMed]  [PMC] 
  5. Pallotta AM, Kim C, Gordon SM, Kim A. Monoclonal antibodies for treating COVID-19. Cleve Clin J Med. 2021 Feb 17. [Crossref]  [PubMed] 
  6. Parry NMA. COVID-19 and pets: When pandemic meets panic. Forensic Science International: Reports. 2020;2100090. [Crossref]  [PMC] 
  7. Sharun K, Tiwari R, Saied AA, Dhama K. SARS-CoV-2 vaccine for domestic and captive animals: An effort to counter COVID-19 pandemic at the human-animal interface. Vaccine. 2021;39(49):7119-22. [Crossref]  [PubMed]  [PMC] 
  8. Sharun K, Tiwari R, Patel SK, Karthik K, Iqbal Yatoo M, Malik YS, et al. Coronavirus disease 2019 (COVID-19) in domestic animals and wildlife: advances and prospects in the development of animal models for vaccine and therapeutic research. Hum Vaccin Immunother. 2020;16(12):3043-54. [Crossref]  [PubMed]  [PMC] 
  9. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446. [Crossref]  [PubMed]  [PMC] 
  10. LiveScience [Internet]. © Future US, Inc. [Cited: July 1, 2022]. Bryner J. Cat infected with COVID-19 from owner in Belgium. Available from: [Link] 
  11. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. Inflamm Regen. 2020;40:37. [Crossref]  [PubMed]  [PMC] 
  12. Carlos WG, Gross JE, Cruz CD, Jamil S. Monoclonal antibodies: medical uses for the prevention and treatment of disease. Am J Respir Crit Care Med. 2021;203(11):P26-7. [Crossref]  [PubMed] 
  13. Sharun K, Dhama K. COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic. Arch Med Res. 2021;52(7):761-3. [Crossref]  [PubMed]  [PMC] 
  14. Deeks ED. Casirivimab/imdevimab: first approval. Drugs. 2021;81(17):2047-55. [Crossref]  [PubMed]  [PMC] 
  15. Hurt AC, Wheatley AK. Neutralizing antibody therapeutics for COVID-19. Viruses. 2021;13(4):628. [Crossref]  [PubMed]  [PMC] 
  16. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. [Crossref]  [PubMed] 
  17. Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai SK. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100-17. [Crossref]  [PubMed]  [PMC] 
  18. Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine. 2021;40:101102. [Crossref]  [PubMed]  [PMC] 
  19. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol. 2021;145:105026. [Crossref]  [PubMed]  [PMC] 
  20. Nhean S, Varela ME, Nguyen YN, Juarez A, Huynh T, Udeh D, et al. COVID-19: a review of potential treatments (corticosteroids, remdesivir, tocilizumab, bamlanivimab/etesevimab, and casirivimab/ımdevimab) and pharmacological considerations. J Pharm Pract. 2021:8971900211048139. [Crossref]  [PubMed]  [PMC] 
  21. Food and Drug Administration. Fact Sheet For Health Care Providers Emergency Use Authorization (Eua) Of REGEN-COV® (Casirivimab and Imdevimab), [Cited: July 10, 2022]. Available from: [Link] 
  22. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3-10. [Crossref]  [PubMed]  [PMC] 
  23. Mizuno T, Kato Y, Kaneko MK, Sakai Y, Shiga T, Kato M, et al. Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment. Sci Rep. 2020;10(1):11476. [Crossref]  [PubMed]  [PMC] 
  24. Van Brussel L, Moyaert H, Escalada M, Mahabir SP, Stegemann MR. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis. Vet Dermatol. 2021;32(5):477-e131. [Crossref]  [PubMed]  [PMC] 
  25. Baum A, Ajithdoss D, Copin R, Zhou A, Lanza K, Negron N, et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370(6520):1110-5. [Crossref]  [PubMed]  [PMC] 
  26. World Organisation for Animal Health (WOAH). SARS-CoV-2 in Animals - Situation Report 14. [Cited: June 30, 2022]. Available from: [Link] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com